These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 34153661)

  • 41. Mechanisms of primary and acquired resistance to PD-1/PD-L1 blockade and the emerging role of gut microbiome.
    Zou R; Wang Y; Ye F; Zhang X; Wang M; Cui S
    Clin Transl Oncol; 2021 Nov; 23(11):2237-2252. PubMed ID: 34002348
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy.
    Wang Y; Gu T; Tian X; Li W; Zhao R; Yang W; Gao Q; Li T; Shim JH; Zhang C; Liu K; Lee MH
    Front Immunol; 2021; 12():654463. PubMed ID: 34054817
    [TBL] [Abstract][Full Text] [Related]  

  • 43. SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges.
    Chen Y; Gao M; Huang Z; Yu J; Meng X
    J Hematol Oncol; 2020 Jul; 13(1):105. PubMed ID: 32723363
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The Triple Positivity for EBV, PD-1, and PD-L1 Identifies a Very High Risk Classical Hodgkin Lymphoma.
    Ozturk V; Yikilmaz AS; Kilicarslan A; Bakanay SM; Akinci S; Dilek İ
    Clin Lymphoma Myeloma Leuk; 2020 Jul; 20(7):e375-e381. PubMed ID: 32295735
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The Evolving Landscape of PD-1/PD-L1 Pathway in Head and Neck Cancer.
    Qiao XW; Jiang J; Pang X; Huang MC; Tang YJ; Liang XH; Tang YL
    Front Immunol; 2020; 11():1721. PubMed ID: 33072064
    [TBL] [Abstract][Full Text] [Related]  

  • 46. PD1 and PD-L1 Inhibitors for the Treatment of Kidney Cancer: The Role of PD-L1 Assay.
    Cimadamore A; Massari F; Santoni M; Lopez-Beltran A; Cheng L; Scarpelli M; Montironi R; Moch H
    Curr Drug Targets; 2020; 21(16):1664-1671. PubMed ID: 32208115
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Rapid T-cell lymphoma progression associated with immune checkpoint inhibitors.
    Ohmoto A; Fuji S
    Expert Rev Hematol; 2023; 16(7):535-541. PubMed ID: 37191476
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Recent advances in the clinical development of immune checkpoint blockade therapy.
    Ghahremanloo A; Soltani A; Modaresi SMS; Hashemy SI
    Cell Oncol (Dordr); 2019 Oct; 42(5):609-626. PubMed ID: 31201647
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Increased level of myeloid-derived suppressor cells, programmed death receptor ligand 1/programmed death receptor 1, and soluble CD25 in Sokal high risk chronic myeloid leukemia.
    Christiansson L; Söderlund S; Svensson E; Mustjoki S; Bengtsson M; Simonsson B; Olsson-Strömberg U; Loskog AS
    PLoS One; 2013; 8(1):e55818. PubMed ID: 23383287
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Programmed Death Ligand 1 (PD-L1) Expression in Lymphomas: State of the Art.
    Zanelli M; Fragliasso V; Parente P; Bisagni A; Sanguedolce F; Zizzo M; Broggi G; Ricci S; Palicelli A; Foroni M; Gozzi F; Gentile P; Morini A; Koufopoulos N; Caltabiano R; Cimino L; Fabozzi M; Cavazza A; Neri A; Ascani S
    Int J Mol Sci; 2024 Jun; 25(12):. PubMed ID: 38928153
    [TBL] [Abstract][Full Text] [Related]  

  • 51. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
    Xia L; Liu Y; Wang Y
    Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Blockade of PD-1, PD-L1, and TIM-3 Altered Distinct Immune- and Cancer-Related Signaling Pathways in the Transcriptome of Human Breast Cancer Explants.
    Saleh R; Toor SM; Al-Ali D; Sasidharan Nair V; Elkord E
    Genes (Basel); 2020 Jun; 11(6):. PubMed ID: 32616706
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Resistance mechanisms to checkpoint inhibitors.
    Weiss SA; Sznol M
    Curr Opin Immunol; 2021 Apr; 69():47-55. PubMed ID: 33676271
    [TBL] [Abstract][Full Text] [Related]  

  • 54. PD-1 expression and clinical PD-1 blockade in B-cell lymphomas.
    Xu-Monette ZY; Zhou J; Young KH
    Blood; 2018 Jan; 131(1):68-83. PubMed ID: 29118007
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Mechanistic insight of predictive biomarkers for antitumor PD‑1/PD‑L1 blockade: A paradigm shift towards immunome evaluation (Review).
    You W; Shang B; Sun J; Liu X; Su L; Jiang S
    Oncol Rep; 2020 Aug; 44(2):424-437. PubMed ID: 32627031
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Increased expression of immune checkpoint programmed cell death protein-1 (PD-1) on T cell subsets of bone marrow aspirates in patients with B-Lymphoblastic leukemia, especially in relapse and at diagnosis.
    Park SH; You E; Park CJ; Cho YU; Jang S; Im HJ; Seo JJ; Park HS; Lee JH
    Cytometry B Clin Cytom; 2020 Jul; 98(4):336-347. PubMed ID: 32268011
    [TBL] [Abstract][Full Text] [Related]  

  • 57. New advances in the treatment of chondrosarcoma under the PD-1/PD-L1 pathway.
    Yin J; Ren P
    J Cancer Res Ther; 2024 Apr; 20(2):522-530. PubMed ID: 38687921
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Programmed Death-1/Programmed Death-Ligand 1-Axis Blockade in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Stratified by Human Papillomavirus Status: A Systematic Review and Meta-Analysis.
    Xu Y; Zhu G; Maroun CA; Wu IXY; Huang D; Seiwert TY; Liu Y; Mandal R; Zhang X
    Front Immunol; 2021; 12():645170. PubMed ID: 33897693
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Treatment beyond progression with anti-PD-1/PD-L1 based regimens in advanced solid tumors: a systematic review.
    Spagnolo F; Boutros A; Cecchi F; Croce E; Tanda ET; Queirolo P
    BMC Cancer; 2021 Apr; 21(1):425. PubMed ID: 33865350
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Immunotherapy with PD-1 and PD-L1 inhibitors for prostate cancer].
    Huang L; He J
    Zhonghua Nan Ke Xue; 2020 Nov; 26(10):944-948. PubMed ID: 33382229
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.